SEP 08, 2020 12:00 PM PDT

Keynote Presentation: Structure-based Vaccine Design for COVID-19 and other Respiratory Viruses

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Deputy Director, Vaccine Research Center, Chief, Viral Pathogenesis Laboratory, NIAID (National Institute of Allergy and Infectious Diseases)
    Biography

      Dr. Graham is Deputy Director and Chief of the Viral Pathogenesis Laboratory at the NIAID Vaccine Research Center. He has a BA from Rice University, an MD from the University of Kansas School of Medicine, and a PhD in Microbiology & Immunology from Vanderbilt University School of Medicine. His primary interests are vaccine development for viral diseases, viral pathogenesis, mechanisms of immunity, and pandemic preparedness. His laboratory has developed novel vaccines for RSV, influenza, Zika, and coronaviruses including the first COVID-19 vaccine and monoclonal antibody products to enter clinical testing.


    Abstract

    While the frequency of pandemic threats seems to be increasing, we fortunately have new tools and technologies to make vaccines with more precision and speed and that support a more proactive approach to pandemic preparedness and response. There are ~25 virus families associated with human infection from which the next pandemic threat will likely arise. Within each relevant virus family, a database of information with accompanying reagents, assays, and animal models could be developed for prototypic viruses based on properties of tropism, transmission routes, and other distinguishing features of pathogenesis. Candidate vaccine approaches could be designed based on virus structure, transmission dynamics, entry requirements, and replication strategy. The prototype pathogen approach for pandemic preparedness has been applied to MERS CoV over the last 7 years. It was informed by structure-based immunogen-design concepts established for RSV F subunit vaccines, and focused on solving coronavirus spike structures, defining mechanisms of CoV neutralization, and evaluating MERS CoV vaccine candidates in collaboration with a commercial mRNA manufacturer. Prior spike protein engineering experience resulted in rapid sequence selection and using the mRNA manufacturing platform provided rapid GMP production a COVID-19 mRNA vaccine in record time. This candidate was tested in mice in ~25 days and humans in ~65 days from the time sequence was released. The product has been shown to be immunogenic and protective in mice, hamsters, and NHP and no safety signals have been noted. Phase 1 and 2 clinical trials demonstrated that mRNA-1273 is well tolerated and immunogenic. These data supported initiation of a 30,000 subject Phase 3 trial on July 27th, 198 days from sequence availability. The proactive preparation not only facilitated rapid vaccine development and evaluation but provided stabilized spike protein reagents that were the basis for developing serological assays and isolating potent human neutralizing mAbs being clinically evaluated for prevention and therapy.

    Learning Objectives:

    1. Understand the prototype pathogen approach for pandemic preparedness and role of new technologies particularly structure-based vaccine design

    2. Know which types of COVID-19 vaccines have advanced into clinical vaccine trials


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    Loading Comments...
    Show Resources